Previous 10 | Next 10 |
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 PR Newswire CAMBRIDGE, Mass. , March 5, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biophar...
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire Well-capitalized with operating runway anticipated into 2027 CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewsw...
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 PR Newswire CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted thera...
2024-02-23 18:33:26 ET More on Nuvalent Nuvalent: Strong Data, But Properly Valued Nuvalent announces 'OnTarget 2026' operating plan; aims for first approved product in 2026 Seeking Alpha’s Quant Rating on Nuvalent Historical earnings data for Nuvalent...
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors PR Newswire Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with...
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference PR Newswire CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisel...
2024-01-16 07:00:00 ET Summary Small cap stocks surged in the final two months of the year as the 10-year yield reversed direction. The Fed's actions in 2024 will determine the prospects for small cap stocks, with a rate cut in March improving their prospects. Small caps may f...
2024-01-10 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-08 12:21:22 ET More on Nuvalent Nuvalent: Strong Data, But Properly Valued Nuvalent GAAP EPS of -$0.59 misses by $0.01 Nuvalent prices $300 million stock offering Seeking Alpha’s Quant Rating on Nuvalent Historical earnings data for Nuv...
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones PR Newswire Targeting first approved product in 2026 towards realizing mission of bringing new, potential best-in-class treatments to patients with cancer Well-capitalized to support OnTar...
News, Short Squeeze, Breakout and More Instantly...
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor PR Newswire CAMBRIDGE, Mass. , July 22, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company foc...
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 PR Newswire CAMBRIDGE, Mass. , July 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharma...
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer PR Newswire CAMBRIDGE, Mass. , July 11, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely target...